Kingdon Capital Management, L.L.C. Gilead Sciences, Inc. Transaction History
Kingdon Capital Management, L.L.C.
- $639 Million
- Q2 2025
A detailed history of Kingdon Capital Management, L.L.C. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 100,000 shares of GILD stock, worth $12 Million. This represents 0.62% of its overall portfolio holdings.
Number of Shares
100,000Holding current value
$12 Million% of portfolio
0.62%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding GILD
# of Institutions
2,347Shares Held
1.03BCall Options Held
12.1MPut Options Held
9.13M-
Black Rock Inc. New York, NY121MShares$14.5 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.3 Billion0.22% of portfolio
-
State Street Corp Boston, MA59.2MShares$7.09 Billion0.25% of portfolio
-
Capital World Investors Los Angeles, CA46.3MShares$5.55 Billion0.78% of portfolio
-
Wellington Management Group LLP Boston, MA37.5MShares$4.5 Billion0.79% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $150B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...